Transfusion-associated graft versus host disease epidemiology and demographics

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Transfusion-associated graft versus host disease Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Transfusion-associated graft versus host disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Biomarker Panel
Chest X Ray
HLA analysis
Skin Punch Biopsy
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Transfusion-associated graft versus host disease epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Transfusion-associated graft versus host disease epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Transfusion-associated graft versus host disease epidemiology and demographics
CDC on Transfusion-associated graft versus host disease epidemiology and demographics
Transfusion-associated graft versus host disease epidemiology and demographics in the news
Blogs on Transfusion-associated graft versus host disease epidemiology and demographics
Directions to Hospitals Treating Transfusion-associated graft versus host disease
Risk calculators and risk factors for Transfusion-associated graft versus host disease epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

The incidence in immunocompromised patients receiving blood transfusions is estimated to be 0.1 - 1.0%, mortality around 80 - 90%. Mortality is higher in TA-GvHD than in GvHD associated with bone marrow transplantation, where the engrafted lymphoid cells in the bone marrow are of donor origin; therefore, the immune reaction is not directed against them.